KALV (KalVista Pharmaceuticals) Short Interest

View and export this data going back to 2015. Start your Free Trial

What is KalVista Pharmaceuticals Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of KalVista Pharmaceuticals's Short Interest

For the Biotechnology subindustry, KalVista Pharmaceuticals's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

KalVista Pharmaceuticals's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, KalVista Pharmaceuticals's Short Interest distribution charts can be found below:

* The bar in red indicates where KalVista Pharmaceuticals's Short Interest falls into.

KalVista Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » KalVista Pharmaceuticals Inc (NAS:KALV) » Definitions » Short Interest

Comparable Companies

Traded in Other Exchanges

4XC1:Germany

Address

55 Cambridge Parkway, Suite 901 East, Cambridge, MA, USA, 02142

Website

https://www.kalvista.com

KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.

Executives

Paul K. Audhya	officer: Chief Medical Officer	C/O KALVISTA PHARMACEUTICALS, INC., 55 CAMBRIDGE PARKWAY, SUITE 901E, CAMBRIDGE MA 02142
Christopher Yea	officer: Chief Development Officer	ONE KENDALL SQUARE, BUILDING 200, SUITE 2203, CAMBRIDGE MA 02139
Benjamin L Palleiko	officer: CFO and Secretary	C/O KALVISTA PHARMACEUTICALS, INC., ONE KENDALL SQUARE, BLD 200, STE 2203, CAMBRIDGE MA 02139
Edward P. Feener	officer: Chief Scientific Officer	ONE KENDALL SQUARE, BUILDING 200, SUITE 2203, CAMBRIDGE MA 02139
Thomas Andrew Crockett	director, officer: President and CEO	BUILDING 227, TETRICUS SCIENCE PARK, PORTON DOWN, SALISBURY, WILTSHIRE X0 SP4 0JQ
Venrock Healthcare Capital Partners Iii, L.p.	10 percent owner	530 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10036
Albert Cha	director	505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301
Patrick Treanor	director	C/O KALVISTA PHARMACEUTICALS, INC., 55 CAMBRIDGE PARKWAY, SUITE 901E, CAMBRIDGE MA 02142
Michael David Smith	officer: Senior VP, Development	C/O KALVISTA PHARMACEUTICALS, INC., 55 CAMBRIDGE PARKWAY, SUITE 901E, CAMBRIDGE MA 02142
Andreas Maetzel	officer: Senior Vice President Medical	1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Nancy Stuart	director	99 HAYDEN AVENUE, SUITE 500, LEXINGTON MA 02421
Brian Jg Pereira	director	C/O ADVANCED MAGNETICS, INC., 61 MOONEY STREET, CAMBRIDGE MA 02138
Daniel B Soland	director	4560 HORTON STREET,M/S R-422, EMERYVILLE CA 94608
Martin Edwards	director	15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Sv Life Sciences Fund Iv (gp), L.p.	10 percent owner	ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900, BOSTON MA 02108